CTLA4 and melanoma: In B16 melanoma, the combined blockade of CTLA-4 and PD-1 negative co-stimulatory receptors significantly increases the Teff infiltration and production of inflammatory cytokines in tumors, and reduces Tregs and myeloid cells within the tumor, thus counteracting tumor-induced immune suppression and promoting tumor rejection [370].